UPDATED: FDA Advisory Committee Proceedings Going Well For Janssen Pharma

The committee meeting is now on lunch break, until 1:30 p.m. Eastern — but the morning session went quite well, from Janssen’s perspective, I thought. Here are today’s background materials, from FDA.gov, as a PDF file.

I’d be pretty confident that InvokanaTM will see a majority committee vote for approval, later this afternoon/this evening. Of course, the advisory committee is just that — advisory. And so, the full commission at FDA could choose to ignore the committee vote. But it only very rarely does.

So. . . Whitehouse Station ought to buckle-up — now that Singulair® has gone generic, it is true that Januvia® is the single largest seller in Merck’s 2013 portfolio, quarter by quarter. And that may see substantial erosion next quarter, if J&J/Janssen is ready to lauch Invokana on approval day. And you may bet that J&J is.

As ever, do stay tuned.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s